Universidad de Murcia, Departamento de Biologia Celular e Histiologia
Abstract
The combination of insulin and DMSO is a
patented (Publication No US8987199B2), noninvasive,
pharmaceutically strategized preparation for direct noseto-brain delivery (DN2BD) suggested for the treatment
of Alzheimer’s disease (AD). Although its main
ingredients have been individually researched, no
histopathological investigations have been conducted to
address this combination effect on the CNS and nasal
tissues in animals. The present work was, therefore,
designed to investigate the potential histopathological
changes induced by this new pharmaceutical
combination using a newly developed refractory staining
method. The findings presented herein showed no signs
of treatment-related lesions or behavioral changes in
Sprague Dawley rats following a three-month successive
treatment with two strengths of the formula